BioLineRX
BLRX
12 hedge funds and large institutions have $6.14M invested in BioLineRX in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.
0% less ownership
Funds ownership: 0.04% → 0.04% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
9% less capital invested
Capital invested by funds: $6.74M → $6.14M (-$599K)
20% less funds holding
Funds holding: 15 → 12 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
+$324K |
| 2 |
Morgan Stanley
New York
|
+$285K |
| 3 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
+$30.4K |
| 4 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
+$25.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$123K |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$65K |
| 3 |
VanEck Associates
New York
|
-$10K |
| 4 |
NFG
Next Financial Group
Houston,
Texas
|
-$8.03K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$6.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BI
1
BVF Inc
San Francisco,
California
| $3.9M | – | – | – |
|
|
SM
2
Senvest Management
New York
| $1.41M | +$324K | +3,149 | +25% |
|
|
3
Morgan Stanley
New York
| $576K | +$285K | +2,765 | +76% |
|
|
O
4
OrbiMed
New York
| $156K | – | – | – |
|
|
OM
5
Opaleye Management
Boston,
Massachusetts
| $38K | – | – | – |
|
|
CCB
6
Cutter & Co Brokerage
Ballwin,
Missouri
| $27K | +$30.4K | +295 | New |
|
|
CAN
7
Cetera Advisor Networks
El Segundo,
California
| $23K | +$25.7K | +250 | New |
|
|
NFG
8
Next Financial Group
Houston,
Texas
| $10K | -$8.03K | -78 | -41% |
|
|
ADL
9
Asset Dedication LLC
San Francisco,
California
| $1K | – | – | – |
|
|
RE
10
RBC Europe
London,
United Kingdom
| $29 | – | – | – |
|
|
EMG
11
ETF Managers Group
Summit,
New Jersey
| – | -$123K | -1,194 | Closed |
|
|
PF
12
Phoenix Financial
Givatayim,
Israel
| – | -$65K | -643 | Closed |
|
|
13
VanEck Associates
New York
| – | -$10K | -92 | Closed |
|
|
14
Wells Fargo
San Francisco,
California
| – | -$6.9K | -67 | -99% |
|
15
UBS Group
Zurich,
Switzerland
| – | -$3K | -27 | Closed |
|
|
PVH
16
Psagot Value Holdings
Tel Aviv,
Israel
| – | -$1K | -6 | Closed |
|
BLRX Hedge Fund Activity: Q4 2019 in Review
12 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2019, worth a combined $6.14M — down 8.9% from $6.74M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BLRX and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Senvest Management, adding an estimated $324K. The largest seller was ETF Managers Group, exiting entirely with an estimated $123K sold.
- 12 institutional investors held BioLineRX (BLRX) as of Q4 2019, down from 15 in Q3 2019.
- Funds reported $6.14M of BioLineRX stock for Q4 2019, down 8.9% quarter-over-quarter.
- 2 funds opened new BioLineRX positions in Q4 2019 and 5 closed out, a net change of -3 holders.
- The largest BioLineRX buyer in Q4 2019 was Senvest Management, an estimated $324K added.
- The largest BioLineRX seller in Q4 2019 was ETF Managers Group, an estimated $123K sold.
Based on aggregated 13F filings for Q4 2019.